Parameter |
Diagnose |
Specification |
Erenumab |
% |
Galcanezumab |
% |
Sex |
CM |
Women |
51 |
87,93 |
32 |
96,97 |
|
|
Men |
7 |
12,07 |
1 |
3,03 |
|
EM |
Women |
20 |
80,00 |
21 |
91,30 |
|
|
Men |
5 |
20,00 |
2 |
8,70 |
Concomitant preventive treatment |
CM |
Yes |
37 |
63,79 |
22,2 |
67,27 |
|
|
No |
21 |
36,21 |
10,8 |
32,73 |
|
EM |
Yes |
16 |
64,00 |
15,0 |
65,32 |
|
|
No |
9 |
36,00 |
8,0 |
34,68 |
Preventive treatment therapeutic group |
CM |
Antiepileptic |
10 |
27,03 |
9 |
40,54 |
|
|
Beta-blockers |
15 |
40,54 |
12 |
54,05 |
|
|
Antidepressants |
18 |
48,65 |
10 |
45,05 |
|
|
ARA-II |
4 |
10,81 |
1 |
4,50 |
|
|
Calcium antagonists |
0 |
0,00 |
1 |
4,50 |
|
EM |
Antiepileptic |
4 |
25,00 |
6 |
39,94 |
|
|
Beta-blockers |
4 |
25,00 |
4 |
26,62 |
|
|
Antidepressants |
5 |
31,25 |
6 |
39,94 |
|
|
ARA-II |
2 |
12,50 |
1 |
6,66 |
|
|
Calcium antagonists |
2 |
12,50 |
0 |
0,00 |
Concomitant treatment with onabotulinumtoxinA |
CM |
Baseline |
23 |
39,66 |
16 |
48,48 |
|
|
After 3 doses |
23 |
39,66 |
14 |
42,42 |
|
|
After 6 doses |
17 |
29,31 |
13 |
39,39 |
|
EM |
Baseline |
10 |
40,00 |
13 |
56,52 |
|
|
After 3 doses |
10 |
40,00 |
10 |
43,48 |
|
|
After 6 doses |
7 |
28,00 |
9 |
39,13 |
Analgesic medication abuse |
CM |
Yes |
39 |
67,24 |
28 |
84,85 |
|
|
No |
19 |
32,76 |
5 |
15,15 |
|
EM |
Yes |
4 |
16,00 |
16 |
69,57 |
|
|
No |
21 |
84,00 |
7 |
30,43 |